Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
PTEN Antibody, Novus Biologicals™

Rabbit Polyclonal Antibody
Specifications
Antigen | PTEN |
---|---|
Concentration | 0.2mg/mL |
Dilution | Western Blot 0.5 - 1.0 ug/ml, Flow Cytometry 0.5 - 1 ug/million cells in 0.1 ml, Immunohistochemistry-Paraffin 1:10-1:500, Immunofluorescence 1 - 2 ug/ml |
Applications | Western Blot, Flow Cytometry, Immunohistochemistry (Paraffin), Immunofluorescence |
Classification | Polyclonal |
Catalog Number | Mfr. No. | Quantity | Price | Quantity & Availability | |||||
---|---|---|---|---|---|---|---|---|---|
Catalog Number | Mfr. No. | Quantity | Price | Quantity & Availability | |||||
NBP24453802
![]() |
Novus Biologicals
NBP2445380.2MG |
0.2 mg | N/A | N/A | N/A | ||||
Description
Specifically detects PTEN in Human, Mouse samples, and it is validated for Flow Cytometry, Immunofluorescence, Western Blotting
PTEN Polyclonal specifically detects PTEN in Human, Mouse samples. It is validated for Western Blot, Flow Cytometry, Immunohistochemistry, Immunohistochemistry-Paraffin, Immunofluorescence.Specifications
PTEN | |
Western Blot 0.5 - 1.0 ug/ml, Flow Cytometry 0.5 - 1 ug/million cells in 0.1 ml, Immunohistochemistry-Paraffin 1:10-1:500, Immunofluorescence 1 - 2 ug/ml | |
Polyclonal | |
Purified | |
RUO | |
10mM PBS and 0.05% BSA with 0.05% Sodium Azide | |
BZS, EC 3.1.3.16,10q23del, EC 3.1.3.48, EC 3.1.3.67, GLM2, MMAC1 phosphatase and tensin homolog deleted on chromosome 10, MMAC1MGC11227, Mutated in multiple advanced cancers 1, phosphatase and tensin homologDEC, phosphatidylinositol-34,5-trisphosphate 3-phosphatase and dual-specificityprotein phosphatase PTEN, PTEN1, TEP1MHAM | |
PTEN | |
IgG | |
Protein A purified | |
Recognizes a protein of 55kDa, which is identified as PTEN. PTEN is one of the most commonly lost tumor suppressors in human cancer; in fact, up to 70% of men with prostate cancer are estimated to have lost a copy of the PTEN gene at the time of diagnosis. During tumor development, mutations and deletions of PTEN occur that inactivate its enzymatic activity leading to increased cell proliferation and reduced cell death. Frequent genetic inactivation of PTEN occurs in glioblastoma, endometrial cancer, and prostate cancer; and reduced expression is found in many other tumor types such as lung and breast cancer. In breast and prostate cancer, loss of PTEN expression has been shown to correlate positively with advanced stage. Furthermore, PTEN mutation also causes a variety of inherited predispositions to cancer. |
0.2mg/mL | |
Western Blot, Flow Cytometry, Immunohistochemistry (Paraffin), Immunofluorescence | |
Unconjugated | |
Rabbit | |
Human, Mouse | |
P60484 | |
5728 | |
Recombinant full-length human PTEN protein | |
Primary | |
Store at 4C. | |
55 kDa |
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title